AEterna Zentaris Inc. (AEZS)

Last Price: 0.43 (2020-08-03)

Company Description

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.53M
Net Income (Most Recent Fiscal Year) $-6.04M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 12.18
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 6.53
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -34.07%
Net Margin (Trailing 12 Months) -22.21%
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -1.67%
Current Ratio (Most Recent Fiscal Quarter) 3.46
Quick Ratio (Most Recent Fiscal Quarter) 3.35
Debt to Common Equity (Most Recent Fiscal Quarter) 0.09
Inventory Turnover (Trailing 12 Months) 1.87
Book Value per Share (Most Recent Fiscal Quarter) $-0.12
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) $-0.02
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 41.13M
Free Float --
Market Capitalization $19.31M
Average Volume (Last 20 Days) 7.08M
Beta (Past 60 Months) 1.81
Percentage Held By Insiders (Latest Annual Proxy Report) --
Percentage Held By Institutions (Latest 13F Reports) 5.12%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%